Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
<h4>Objectives</h4> <p>To evaluate the benefits and harms of oral centrally acting antiobesity medicinal products in pivotal trials.</p> <h4>Methods</h4> <p>The European Medicines Agency and Federal Drug Administration websites, PubMed, and ClinicalTrials....
Päätekijät: | Onakpoya, I, Collins, D, Bobrovitz, N, Aronson, J, Heneghan, C |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
Wiley
2018
|
Aiheet: |
Samankaltaisia teoksia
-
Lorcaserin in obesity: minimal benefits and ill-defined harms
Tekijä: Onakpoya, I, et al.
Julkaistu: (2019) -
Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials
Tekijä: Onakpoya, I, et al.
Julkaistu: (2019) -
Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials
Tekijä: Igho J Onakpoya, et al.
Julkaistu: (2019-01-01) -
Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
Tekijä: Onakpoya, I, et al.
Julkaistu: (2016) -
Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
Tekijä: Onakpoya, I, et al.
Julkaistu: (2017)